CATX

Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on developing targeted alpha-particle therapies (TATs) for cancer treatment. The company utilizes proprietary radioisotope technology, specifically Pb-212-based therapies, to deliver radiation directly to cancer cells while minimizing damage to healthy tissue. Its pipeline includes image-guided alpha-particle therapies for various cancers, including neuroendocrine tumors, melanoma, and solid tumors, leveraging high-affinity targeting peptides for enhanced treatment efficacy.